US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

AstraZeneca ($AZN) won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The ...

The US Food and Drug Administration (FDA) has approved extended-release exenatide in a pen form for the treatment of adults with type 2 diabetes, according to the manufacturer. AstraZeneca's exenatide ...

The FDA has approved Bydureon Pen (exenatide extended-release for injectable suspension; Bristol-Myers Squibb and AstraZeneca) as an adjunct to diet and exercise to improve glycemic control in adults ...

Bydureon BCise was discontinued by its manufacturer AstraZeneca on October 28, 2024. This drug is no longer available in the United States. Discontinuation of Bydureon BCise was a business decision by ...

Amylin said weekly diabetes shot Bydureon, launched in February, is gaining market share among influential physicians but expects the med’s profit margins to be low for some time. Bydureon brought in ...

WILMINGTON, Del. -- AstraZeneca has received regulatory approval for a single-use pen injector designed to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence ...

Amylin said Tuesday that quarterly sales fell 5.3% to $165 million for the period ended December 31 as Byetta sales declined. Sales for the year fell 2%, to $651 million for the year ended December 31 ...

As pundits continue to ponder the unanswered questions surrounding Amylin Pharmaceuticals and its rejection of a bid by Bristol-Myers Squibb – did the big drugmaker really make a bid? if so, when? and ...